MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

NCT07505303 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tests whether a combination of semaglutide and THR-β therapy can help adults with obesity manage their weight over a 20-week period.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 160 people Planned (estimated).

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2026-03 · est. completion 2026-11

Where 15 sites · United States

What this study is testing ClinicalTrials.gov NCT07505303 ↗

Description as written by the study sponsor.

The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.

Treatments tested

ECC4703 Drug

orally QD
Placebo Drug

orally QD
Semaglutide Drug

SC once weekly

Main thing measured	Percentage Change in Body Weight from Baseline (Week 9) to Week 20
Sponsor	Eccogene
Conditions studied	Adult Obesity, Weight Management
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07505303 ↗